Aclaris Therapeutics Net Income
| ACRS Stock | USD 3.26 0.07 2.19% |
As of the 19th of February, Aclaris Therapeutics shows the Downside Deviation of 4.77, risk adjusted performance of 0.0815, and Mean Deviation of 4.51. Aclaris Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Aclaris Therapeutics downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Aclaris Therapeutics is priced correctly, providing market reflects its regular price of 3.26 per share. Given that Aclaris Therapeutics has jensen alpha of 0.7952, we suggest you to validate Aclaris Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.
Aclaris Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 14.4163 | Revenue | Earnings Share (1.58) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -118.9 M | -112.9 M | |
| Net Loss | -118.9 M | -124.8 M | |
| Net Loss | -78.2 M | -82.1 M | |
| Net Loss | (1.54) | (1.61) | |
| Net Income Per E B T | 1.15 | 1.21 |
Aclaris | Net Income | Build AI portfolio with Aclaris Stock |
The evolution of Net Income for Aclaris Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Aclaris Therapeutics compares to historical norms and industry peers.
Latest Aclaris Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Aclaris Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Aclaris Therapeutics financial statement analysis. It represents the amount of money remaining after all of Aclaris Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Aclaris Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aclaris Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (132.06 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Aclaris Net Income Regression Statistics
| Arithmetic Mean | (67,873,584) | |
| Coefficient Of Variation | (79.30) | |
| Mean Deviation | 46,321,373 | |
| Median | (68,523,000) | |
| Standard Deviation | 53,822,332 | |
| Sample Variance | 2896.8T | |
| Range | 156.1M | |
| R-Value | (0.82) | |
| Mean Square Error | 1027.8T | |
| R-Squared | 0.67 | |
| Significance | 0.000063 | |
| Slope | (8,707,184) | |
| Total Sum of Squares | 46349.5T |
Aclaris Net Income History
Other Fundumenentals of Aclaris Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Aclaris Therapeutics Net Income component correlations
Aclaris Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Aclaris Therapeutics is extremely important. It helps to project a fair market value of Aclaris Stock properly, considering its historical fundamentals such as Net Income. Since Aclaris Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aclaris Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aclaris Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Pharmaceuticals market expansion? Will Aclaris introduce new products? Factors like these will boost the valuation of Aclaris Therapeutics. If investors know Aclaris will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Aclaris Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.58) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets | Return On Equity |
Understanding Aclaris Therapeutics requires distinguishing between market price and book value, where the latter reflects Aclaris's accounting equity. The concept of intrinsic value - what Aclaris Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Aclaris Therapeutics' price substantially above or below its fundamental value.
Understanding that Aclaris Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aclaris Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Aclaris Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Aclaris Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Aclaris Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Aclaris Therapeutics.
| 11/21/2025 |
| 02/19/2026 |
If you would invest 0.00 in Aclaris Therapeutics on November 21, 2025 and sell it all today you would earn a total of 0.00 from holding Aclaris Therapeutics or generate 0.0% return on investment in Aclaris Therapeutics over 90 days. Aclaris Therapeutics is related to or competes with Cabaletta Bio, Exagen, Editas Medicine, NeoGenomics, Senseonics Holdings, Allogene Therapeutics, and MDxHealth. Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immun... More
Aclaris Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Aclaris Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Aclaris Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.77 | |||
| Information Ratio | 0.0865 | |||
| Maximum Drawdown | 84.2 | |||
| Value At Risk | (7.77) | |||
| Potential Upside | 8.62 |
Aclaris Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aclaris Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Aclaris Therapeutics' standard deviation. In reality, there are many statistical measures that can use Aclaris Therapeutics historical prices to predict the future Aclaris Therapeutics' volatility.| Risk Adjusted Performance | 0.0815 | |||
| Jensen Alpha | 0.7952 | |||
| Total Risk Alpha | 0.4251 | |||
| Sortino Ratio | 0.1751 | |||
| Treynor Ratio | 0.4142 |
Aclaris Therapeutics February 19, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0815 | |||
| Market Risk Adjusted Performance | 0.4242 | |||
| Mean Deviation | 4.51 | |||
| Semi Deviation | 4.4 | |||
| Downside Deviation | 4.77 | |||
| Coefficient Of Variation | 1094.47 | |||
| Standard Deviation | 9.66 | |||
| Variance | 93.28 | |||
| Information Ratio | 0.0865 | |||
| Jensen Alpha | 0.7952 | |||
| Total Risk Alpha | 0.4251 | |||
| Sortino Ratio | 0.1751 | |||
| Treynor Ratio | 0.4142 | |||
| Maximum Drawdown | 84.2 | |||
| Value At Risk | (7.77) | |||
| Potential Upside | 8.62 | |||
| Downside Variance | 22.78 | |||
| Semi Variance | 19.36 | |||
| Expected Short fall | (5.84) | |||
| Skewness | 5.49 | |||
| Kurtosis | 39.07 |
Aclaris Therapeutics Backtested Returns
Aclaris Therapeutics appears to be very risky, given 3 months investment horizon. Aclaris Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0818, which signifies that the company had a 0.0818 % return per unit of risk over the last 3 months. By analyzing Aclaris Therapeutics' technical indicators, you can evaluate if the expected return of 0.83% is justified by implied risk. Please makes use of Aclaris Therapeutics' Downside Deviation of 4.77, mean deviation of 4.51, and Risk Adjusted Performance of 0.0815 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Aclaris Therapeutics holds a performance score of 6. The firm shows a Beta (market volatility) of 2.11, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Aclaris Therapeutics will likely underperform. Please check Aclaris Therapeutics' downside variance, and the relationship between the sortino ratio and accumulation distribution , to make a quick decision on whether Aclaris Therapeutics' price patterns will revert.
Auto-correlation | 0.83 |
Very good predictability
Aclaris Therapeutics has very good predictability. Overlapping area represents the amount of predictability between Aclaris Therapeutics time series from 21st of November 2025 to 5th of January 2026 and 5th of January 2026 to 19th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Aclaris Therapeutics price movement. The serial correlation of 0.83 indicates that around 83.0% of current Aclaris Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.83 | |
| Spearman Rank Test | 0.46 | |
| Residual Average | 0.0 | |
| Price Variance | 0.37 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Aclaris Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Aclaris Therapeutics reported net income of (132.06 Million). This is 138.7% lower than that of the Pharmaceuticals sector and 176.29% lower than that of the Health Care industry. The net income for all United States stocks is 123.13% higher than that of the company.
Aclaris Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aclaris Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aclaris Therapeutics could also be used in its relative valuation, which is a method of valuing Aclaris Therapeutics by comparing valuation metrics of similar companies.Aclaris Therapeutics is currently under evaluation in net income category among its peers.
Aclaris Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Aclaris Therapeutics from analyzing Aclaris Therapeutics' financial statements. These drivers represent accounts that assess Aclaris Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Aclaris Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 275.2M | 824.9M | 73.3M | 191.7M | 220.5M | 423.2M | |
| Enterprise Value | 264.4M | 798.2M | 33.8M | 167.1M | 192.2M | 373.0M |
Aclaris Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Aclaris Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Aclaris Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Aclaris Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Aclaris Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Aclaris Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aclaris Therapeutics' value.| Shares | Marshall Wace Asset Management Ltd | 2025-06-30 | 2.3 M | Logos Global Management Lp | 2025-06-30 | 1.9 M | Renaissance Technologies Corp | 2025-06-30 | 1.5 M | Palo Alto Investors, Llc | 2025-06-30 | 1.4 M | Bollard Group Llc | 2025-06-30 | 1.4 M | Citadel Advisors Llc | 2025-06-30 | 1.1 M | State Street Corp | 2025-06-30 | 1 M | Deutsche Bank Ag | 2025-06-30 | 1 M | Aldebaran Capital Llc | 2025-06-30 | 993.7 K | Bml Capital Management Llc | 2025-06-30 | 14.2 M | Adage Capital Partners Gp Llc | 2025-06-30 | 9.6 M |
Aclaris Fundamentals
| Return On Equity | -1.13 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (5.17) % | ||||
| Current Valuation | 226.94 M | ||||
| Shares Outstanding | 108.35 M | ||||
| Shares Owned By Insiders | 2.95 % | ||||
| Shares Owned By Institutions | 76.76 % | ||||
| Number Of Shares Shorted | 4.99 M | ||||
| Price To Earning | (12.14) X | ||||
| Price To Book | 2.88 X | ||||
| Price To Sales | 22.44 X | ||||
| Revenue | 18.72 M | ||||
| Gross Profit | (43.4 M) | ||||
| EBITDA | (51.72 M) | ||||
| Net Income | (132.06 M) | ||||
| Cash And Equivalents | 248.6 M | ||||
| Cash Per Share | 3.73 X | ||||
| Total Debt | 2.6 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.99 X | ||||
| Book Value Per Share | 1.11 X | ||||
| Cash Flow From Operations | (20.07 M) | ||||
| Short Ratio | 1.70 X | ||||
| Earnings Per Share | (1.58) X | ||||
| Price To Earnings To Growth | (0.13) X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 61 | ||||
| Beta | 0.87 | ||||
| Market Capitalization | 353.21 M | ||||
| Total Asset | 220.33 M | ||||
| Retained Earnings | (902.86 M) | ||||
| Working Capital | 94.36 M | ||||
| Current Asset | 86.52 M | ||||
| Current Liabilities | 1.55 M | ||||
| Net Asset | 220.33 M |
About Aclaris Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aclaris Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aclaris Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aclaris Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.